

## Index

*Abbreviations used:* HLH, hemophagocytic lymphohistiocytosis; LCH, Langerhans cell histiocytosis

- acute myeloid leukaemia (AML) 396, 397–401
- adult-onset Still's disease (AOSD) 382
- antigen presentation 44–5
- apoptosis, in HLH 337–8
  - perforin role 340
- benign cephalic histiocytosis (BCH) 141, 294–7, 304
- bisphosphonate therapy 166
- bone disease
  - Erdheim–Chester disease (ECD) 19, 307–10
  - LCH 15–20, 95–103, 154–70
    - clinical aspects 154
    - clinical presentation 154–6
    - craniofacial bones 210–11, 215, 223, 277
    - late sequelae 274–5
    - orbits 116–17, 158–60, 169, 210–11
    - orthopaedic disabilities 274–5
    - reactivation of disease 169–70
    - skull base lesions 210–11
    - spine 156–7, 168
    - temporal bone 157–8, 168–9
  - radiologic investigations 160–5
    - bone scintigraphy 161–2
    - coincidence FDG PET scan 164–5
    - computerized tomography 162
    - magnetic resonance imaging 163
    - plain radiographs 160–1
    - therapy 165–7, 236–48
      - bisphosphonate therapy 166
      - chemotherapy 166–7
      - intralesional steroid 165
      - multifocal disease 237–8
      - 'non-risk' bones 167
      - non-steroidal anti-inflammatory drugs 165
      - radiation therapy 166
      - 'risk' bones 168–9
      - therapeutic decision-making 167–9
      - unifocal disease 237–8
- bone marrow
  - HLH 331
  - familial (FHL) 321–30
  - LCH 27–8, 109–10
- brain lesions *see* central nervous system (CNS) involvement
- bronchiolar destruction 193–4
- bronchoalveolar lavage 198–9
- bronchoscopy 198
- CCL20 72–3
- CD1a 14–18
- cell cycle regulation, LCH 73–5
- central nervous system (CNS) involvement
  - HLH 328–30
  - therapy 361
  - LCH 28–9, 109, 208–24

**418** Index

- central nervous system (CNS) involvement  
 (*contd*)  
 craniofacial bone and skull base lesions  
 210–11, 234–5, 236  
 granulomas 208–9, 218  
 intracranial–extra-axial disease 211–16  
 intracranial–intraparenchymal disease  
 216–22  
 late sequelae 278–80  
 management 222, 357, 391  
 risk factors 280
- cerebellar involvement, LCH 218–19, 278
- Chediak–Higashi syndrome (CHS) 345, 356,  
 357
- chemokine role in LCH 71–3
- chemotherapy 166, 254  
 adults 178–82  
 bone disease 154, 166–7, 236–7  
 CNS lesions 215–16, 222, 238–9  
 HLH 359, 361–6  
 Epstein–Barr virus-associated HLH 369  
 lung disease 30, 238, 278  
 macrophage-activation syndrome 357, 389  
 multisystem disease 238, 239–248  
 conservative approach 238, 239–40  
 intensive chemotherapy 240  
 international clinical trials 240–244  
 refractory disease 254–55, 260, 369  
 sinus histiocytosis with massive  
 lymphadenopathy (SHML) 314, 315
- children  
 gastrointestinal involvement 32  
 lung disease 238, 278  
 skin histiocytoses 20–1, 103, 130, 132–7, 238  
 benign cephalic histiocytosis (BCH) 141  
 generalized eruptive histiocytomas 142  
 HLH 142  
*see also specific conditions*
- 2-chlorodeoxyadenosine 255–7
- choroid plexus lesions, in LCH 215–16
- chronic myelomonocytic leukaemia (CMML)  
 401–2
- competence, focus of 415
- computerized tomography (CT)  
 bone disease 162  
 pulmonary disease 196–7
- congenital self-healing reticulohistiocytosis  
 (CSRH) 135–6  
*see also* Hashimoto–Pritzker disease
- corticosteroids *see* steroid therapy
- craniofacial bone lesions 210–11, 236,  
 237  
 late sequelae 274–5  
*see also* bone disease; orbital lesions
- cutaneous indeterminate cell histiocytosis  
 (CICH) 145–6
- cutaneous lesions *see* skin histiocytoses
- cyclosporin A (CSA)  
 HLH treatment 360, 364, 365  
 LCH treatment 255–6  
 macrophage-activation syndrome  
 treatment 389, 391
- cytokine storm role in LCH 69–71
- dendritic cells (DCs) 15, 293–4  
 distinction from macrophages 51–2  
 functional heterogeneity 42–8  
 antigen presentation 44–5  
 endocytosis 42–4  
 regulatory functions 45–8  
 heterogeneity in origins 52–4  
 malignancies 404–5  
 follicular dendritic cell (FDC) sarcoma  
 404  
 interdigitating dendritic cell (IDC)  
 sarcoma 405  
 phenotypic heterogeneity 49–51
- development, affects on 413
- diabetes insipidus (DI) 106–8, 212–14,  
 277
- E-cadherin 68
- ears, in LCH 103–5, 276  
 late sequelae 277
- endocytosis 42–4
- Epstein–Barr virus-associated HLH (EBV-  
 HLH) 9, 10, 347, 366–70  
 classification 368  
 clinical features 366–8  
 initial treatment 368  
 late sequelae 370  
 lymphoma-associated HLH and 371

**419**      **Index**

- prognosis 370
- specific therapy 369–70
  - hematopoietic stem cell transplantation 369–70
  - salvage chemotherapy 369
- Erdheim–Chester disease (ECD) 19, 307–10
  - clinical features 308–9
  - therapy 309–10
- erythrophagocytosis 321–2
- etanercept 259–60
- eyes
  - LCH 116–17
  - ocular juvenile xanthogranuloma 302–3
  - see also* orbital lesions
- familial hemophagocytic lymphohistiocytosis (FHL) 9, 321, 322–30, 356
  - bone marrow 323–5
  - CNS 328–30
  - diagnosis 349
  - epidemiology 10
  - historical perspectives 9–10
  - liver 325
  - lung 328
  - lymph node 325–6
  - skin 328
  - spleen 326–7
  - therapy 359–60
  - see also* hemophagocytic lymphohistiocytosis (HLH)
- family issues
  - changes to family life 412
  - collaborative relationships with family members 413–15
  - provider–family relationship 409–11
- fascin 67
- follicular dendritic cell (FDC) sarcoma 404
- gastrointestinal tract, in LCH 32–3, 115–16
- generalized eruptive histiocytosis (GEH) 146, 294, 296, 304–5
- genetic factors
  - HLH 339–44
  - consequences of perforin deficiency 340–1
  - genotype–phenotype correlation studies 342–4
  - linkage analyses 339–40
  - MUNC13-4 mutations 346–7
  - perforin mutations 342
  - perforin role for granule-mediated killing 340
  - SAP mutations 348
- LCH 6–7, 83–92, 120
  - chromosome studies 90–1
  - familial clustering 86
  - genetic models 89
  - LCH association with genetic polymorphism 91
  - twin study 85–6
- X-linked lymphoproliferative disease 347–8
  - Epstein–Barr virus-triggered hemophagocytosis 347
  - SAP mutations 348
  - SAP role in cytotoxicity 348
- glucocorticoid therapy 201–2
- GM-CSF hypersensitivity 403
- granulomas
  - CNS 208–9, 221
  - infiltrating parenchymal LCH granulomas 218
  - see also* xanthogranuloma
- GrisCELLI syndrome 356, 357
- growth hormone deficiency (GHD) 277
- haematopoietic system, in LCH 109–10
- Hand–Schüller–Christian disease 5, 136
  - see also* Langerhans cell histiocytosis (LCH)
- Hashimoto–Pritzker disease 20, 103, 118, 135–6
- hearing loss 276
- hemophagocytic lymphohistiocytosis (HLH) 9–10, 142, 353
  - age at onset 354
  - classification 356–7
  - clinical symptoms 354–5

**420** Index

- hemophagocytic lymphohistiocytosis (HLH) (*contd*)
  - course of disease 355
  - diagnosis 357–9
  - epidemiology 10, 353–4
  - histopathology 321–33
    - primary HLH 322–30
    - secondary HLH 330–3
  - historical perspectives 9–10
  - infection associated 356–7
    - see also* Epstein–Barr virus-associated HLH (EBV-HLH)
  - laboratory findings 355–6
  - lymphoma-associated 370–3
    - clinical features 371–2
    - EBV role 371
    - prognosis 372–3
    - treatment 372–3
    - types of lymphomas 371
  - molecular genetics 339–48
    - consequences of perforin deficiency 340–1
    - genotype–phenotype correlation studies 342–4
    - linkage analyses 339–40
    - Munc13-4 gene deficiency 346–7
    - perforin mutations 342, 343
    - perforin role for granule-mediated killing 340
    - SAP mutations 348
  - pathogenesis 337–9
    - apoptosis pathways 337–8, 340
    - hypercytokinemia 339
    - lymphocyte cytotoxicity dysfunction 338–9
  - therapy 359–66
    - background 359
    - CNS disease 361
    - patients without stem cell transplantation 364
    - reactivation therapy 364, 365–6
    - salvage therapy 365
    - study HLH-94 360–3
    - study HLH-2004 364
    - therapeutic problems 359–60
    - underlying conditions 356–7
      - see also* Epstein–Barr virus-associated HLH (EBV-HLH); familial hemophagocytic lymphohistiocytosis (FHL)
- hemophagocytosis 321–2
- high-resolution computed tomography (HRCT) 196–7
- histiocytes 40
  - characteristics 2
  - development 1–2
  - see also* dendritic cells (DCs); macrophages
- histiocytosis X 5, 95
  - see also* Langerhans cell histiocytosis (LCH)
- histiolytic disorders
  - classification 3–4, 118–19, 131–2, 230–5
  - non-LCH histiocytoses 293–4
  - definition 1, 2
  - diagnosis 2, 297, 298–9
  - see also specific disorders*
- hypercytokinemia
  - in HLH 339
  - in macrophage activation syndrome 386–7
    - control of 389
- hypothalamic syndrome 278
- hypothalamic–pituitary involvement, LCH 105–8, 209, 211–15
- immunotherapy
  - LCH 257–8
  - macrophage-activation syndrome 389–91
- indeterminate cell histiocytosis 305
- indomethacin 165
- infection-associated hemophagocytic syndrome (IAHS) 356–7
  - see also* Epstein–Barr virus-associated HLH (EBV-HLH)
- interdigitating dendritic cell (IDC) sarcoma 405
- interferon therapy 258
- intralesional steroid therapy 165

**421**      **Index**

- juvenile myelomonocytic leukemia (JMML)
  - 297, 401–3
- juvenile xanthogranuloma (JXG) 19–20, 21,
  - 35, 139–41, 294–303
  - clinical features 300
  - cutaneous 300–2
  - histopathology 297–300
  - intraocular 302–3
  - JXG family 294–7
  - systemic 302
  - therapy 303
- Ki-67 73–4
- Kikuchi's disease 386
- Langerhans cell histiocytosis (LCH)
  - 4–8, 14
  - as reactive versus neoplastic disease 77
  - associated diseases 119–20
    - diabetes insipidus 106–9, 277
    - malignancies 280–8
    - other histiocytoses 119
  - cell characteristics *see* LCH cells
  - cell cycle regulation and proliferation
    - 73–5
  - chemokine role 71–3
  - children versus adults 176–8
  - classification 118–19, 231, 234
  - clinical challenge 123–4
  - clinical presentation 132–5, 143
    - in adults 174–6
  - cytokine role 69–71
  - diagnosis 120, 137
    - diagnostic histopathology 14–17
    - differential diagnosis 120–1, 137–8
    - work-up 121–2
  - disease activity assessment 119,
    - 121–2
  - epidemiology 6–7, 117–18
    - age 6–7, 117–18
    - ethnic factors 7
    - gender 7, 117
  - genetics 7, 83–92, 120
    - chromosome studies 90
    - familial clustering 86
    - genetic models 89
    - LCH association with genetic polymorphism 91
    - twin study 85–6
  - historical aspects 5–6
  - late sequelae 123, 272–80, 288–90
    - brain 278–80
    - ears 276
    - endocrine sequelae 277–8
    - liver 280
    - lungs 278
    - orthopaedic disabilities 274–5
    - permanent consequences 247–8, 272, 288
    - skin 276–7
  - outcome and disease dynamics 118
    - adults 182–3
  - prognosis 122–3, 138, 143–4, 249
  - psychosocial aspects 408–16
    - case studies 409–15
  - risk factors 8
  - sites at which LCH is not found 34, 117
  - specific organs and sites 17–33, 95–117
    - blood 109–10
    - bone 17–20, 95–103, 154–70, 274–5
    - bone marrow 28, 109–10
    - central nervous system 28–9, 109, 208–24, 238–9
    - ear, nose and throat 103–5, 276
    - gastrointestinal tract 32, 115–16
    - liver 26–7, 113–14
    - lung 30–31, 110–13, 187–203, 238
    - lymph nodes 24–26, 115, 238
    - mouth and gums 115
    - orbits and eyes 116–17, 158–60, 169, 210–11
    - pituitary 105–9
    - skin 20–3, 103, 130–9, 142–5, 238
    - soft tissue 20, 103
    - spleen 32, 114–15
    - thymus 33–34, 115
    - thyroid 34
    - see also specific sites of disease*
  - stratification systems 230–4
  - survival 122–3
  - treatment 229–48, 254–65
    - basic issue 230–1

**422** Index

- Langerhans cell histiocytosis (LCH) (*contd*)  
 treatment (*contd*)  
   chronic progressive disease 261–3  
   historical perspective 229–30  
   in adults 178–82  
   international clinical trials 240–4  
   multisystem disease 239–44,  
     254–5  
   permanent consequences and 247–8,  
     288  
   refractory disease 247–8, 254–63  
   single-system disease 236–8  
   *see also specific sites of disease; specific  
   therapies*  
   viral infection role 76–7, 84
- Langerhans cell (LC) sarcoma 23
- Langerin 15–17
- late sequelae  
 Epstein–Barr virus-associated HLH (EBV-  
 HLH) 370
- LCH 274–80  
   bone disease 274–5  
   CNS 278–80  
   ears 276  
   liver 280  
   lung 278  
   skin 276–7
- LCH cells 15–17  
   clonal proliferation 75–6  
   immune function 68–9  
   phenotypic characteristics 66–8
- learning difficulties 279–80
- lectin-like receptors 43
- Letterer–Siwe disease 5, 137
- leukaemia  
   acute myeloid leukaemia (AML) 396  
     involving cells of monocyte/macrophage  
     lineage 397–401  
   chronic myelomonocytic leukaemia  
     (CMML) 401–2  
   juvenile myelomonocytic leukemia  
     (JMML) 297, 401–3  
   LCH association 283–8
- liver  
   HLH 332–3  
     familial (FHL) 325  
   LCH 26–7, 113–14  
     chronic progressive disease 263–5  
     late sequelae 280  
     transplantation 265
- lung involvement  
   familial HLH 328  
   *see also pulmonary LCH*
- lung transplantation 265
- lupus hemophagocytic syndrome 384
- lymph node  
   familial HLH 325–6  
   LCH 23–5, 115, 237
- lymphocyte cytotoxicity, in HLH 337–9  
   SAP role 348
- lymphoma  
   anaplastic large cell lymphoma 396–7  
   LCH association 288  
   lymphoma-associated hemophagocytic  
     syndrome (LAHS) 370–3  
     clinical features 371–2  
     EBV role 371  
     prognosis 372–3  
     treatment 372–3  
     types of lymphomas 371
- macrophage-activation syndrome (MAS)  
   357, 382  
   classification among histiocyte disorders  
     381–2  
   historical perspectives 380–1  
   nomenclature issues 380–1  
   prognostic factors 388  
   rheumatic disease-associated 382–8,  
     389  
     diagnostic criteria 387–8  
     hypercytokinemia and 386–7  
     MAS etiopathogenesis 386  
     systemic lupus erythematosus  
       384–5  
     systemic-onset juvenile rheumatoid  
       arthritis (SoJRA) 382–4  
   treatment 389–91
- macrophages  
   distinction from dendritic cells 51–2  
   functional heterogeneity 42–8  
   antigen presentation 44–5

## 423 Index

- endocytosis 42–4
  - regulatory functions 45–8
- heterogeneity in origins 54–6
- phenotypic heterogeneity 48–9
- magnetic resonance imaging (MRI) 163
  - brain abnormalities 279
- malignancy
  - LCH association 280–8
    - acute leukaemia 283–8
    - lymphomas 288
    - solid tumours 281–2
  - monocyte/macrophage system 396–405
    - acute myeloid leukaemia (AML) 397–401
    - chronic myelomonocytic leukaemia (CMML) 401–2
    - dendritic cell malignancies 404–5
    - juvenile myelomonocytic leukaemia (JMML) 297, 401–3
  - meningeal lesions, in LCH 215–16
  - monoclonal antibody therapy 259
  - mononuclear phagocytic system (MPS) 1–2
    - development 1–2, 52–3
    - heterogeneity 40–2
      - functional heterogeneity 42–8
      - in origins 52–6
      - phenotypic heterogeneity 48–51
    - see also* dendritic cells (DCs); macrophages
  - Montgomery syndrome 146–7
  - mouth, in LCH 115
  - multicentric reticulohistiocytosis (MRH) 147, 306–7
    - clinical features 306
    - therapy 307
  - Mun13–4 gene 344
    - mutations in HLH 346–7
    - role in cytotoxic granule exocytosis 345–6
- neurobiotic xanthogranuloma 147
- neurodegenerative disease 218–22
- neurological damage *see* central nervous system (CNS) involvement
- non-steroidal anti-inflammatory drugs (NSAIDs) 165
- nucleoside analog therapy 255–57
- oral lesions, LCH 115
- orbital lesions, LCH 116–17, 158–60, 210–11
  - differential diagnosis 159–60
  - therapy 169
- orthopaedic disease *see* bone disease
- p53 transcription factor 74
- pamidronate 166
- perforin
  - in HLH 340–2
    - consequences of deficiency 340–1
    - mutations 342, 343
    - role in granule-mediated killing 340
    - in macrophage activation syndrome 386
- permanent consequences 247, 272, 288
- phagocytosis 42–4
- pineal gland lesions, LCH 215
- pituitary dysfunction, anterior 277–8
  - see also* hypothalamic–pituitary involvement
- positron emission tomography (PET) 164–5
- post-transplant lymphoproliferative disorder (PTLD) 265
- progressive nodular hyperplasia (PNH) 294–6, 305
- provider–family relationship 409–10
- psychosocial aspects 408–16
  - case studies 409–15
- pulmonary LCH 29–31, 110–13, 187–203
  - bronchoalveolar lavage 198–9
  - bronchoscopy 198
  - chronic progressive disease 263–5
  - clinical presentation 195–6
    - unusual presentations 199
  - course of disease 200
  - diagnosis 199–200
  - epidemiology 187–8
  - laboratory tests 199
  - late sequelae 277
  - lung pathology 188–90
  - pathogenesis 190–5
    - bronchiole destruction 193–4
    - Langerhans cells (LCs) 190–2
    - LC accumulation in lung 192–3

**424** Index

- pulmonary LCH (*contd*)
    - pathogenesis (*contd*)
      - smoking and 194–5
    - prognosis 200–1
    - pulmonary function 197–8
    - radiology 196–7
      - chest radiographs 196
      - high-resolution computed tomography 196–7
    - treatment 201–3, 237, 264–5
  - radiation therapy 166, 236
    - malignancy and 282
  - radiography
    - bone disease 160–1
    - pulmonary disease 196
  - reactivation of disease 169
    - bone disease 169–70
  - relapse *see* reactivation of disease
  - rheumatic diseases, macrophage activation
    - syndrome association 382, 382–8
    - diagnostic criteria 387–8
    - hypercytokinemia and 386–7
    - MAS etiopathogenesis 386
    - systemic lupus erythematosus 384–5
    - systemic-onset juvenile rheumatoid arthritis (SoJRA) 382–4
    - treatment 389
  - risk factors
    - CNS disease 280
    - LCH 8
  - Rosai–Dorfman disease 19, 35, 311
    - cutaneous 313
    - see also* sinus histiocytosis with massive lymphadenopathy (SHML)
  - SAP gene
    - mutations 348
    - role in cytotoxicity 348
  - sarcoma
    - follicular dendritic cell (FDC) 404
    - interdigitating dendritic cell (IDC) 405
  - sclerosing cholangitis (SC) 264, 280
  - seborrhoeic dermatitis 103, 138
  - self-healing reticulohistiocytosis 20
    - congenital 135–6
  - sequelae *see* late sequelae
  - sinus histiocytosis with massive lymphadenopathy (SHML) 35, 311–15
    - clinical course 312–13
    - clinical features 311–12
    - pathology 311
    - therapy 313–15
      - recommendations 314–15
  - skeletal lesions *see* bone disease
  - skin histiocytoses 130–47, 237
    - benign cephalic histiocytosis (BCH) 141, 294–6, 304
    - classification 131–2
    - clinical presentation 132–5, 143
    - cutaneous indeterminate cell histiocytosis (CICH) 145–6
    - cutaneous Rosai–Dorfman disease 313
    - diagnosis 137
      - differential diagnosis 137–8
      - investigations 138
    - generalized eruptive histiocytomas 142
    - generalized eruptive histiocytosis (GEH) 146, 294–6, 304–5
    - HLH 142, 333
      - familial (FHL) 327–8
    - indeterminate cell histiocytosis 305
    - juvenile xanthogranuloma (JXG) 139–41, 300–2
  - LCH 20–3, 103, 130–9, 142–5, 237
    - as part of disseminated disease 137
    - as part of limited MS disease 136
    - epidemiology 130
    - Hashimoto–Pritzker variant 135–6
    - late sequelae 276–7
    - skin-only LCH 135
  - multicentric reticulohistiocytosis 147
  - necrobiotic xanthogranuloma 147
  - pathology 131
  - prognosis 138, 143–5
  - progressive nodular hyperplasia (PNH) 294–6, 305
  - treatment 138–9, 145, 237
  - xanthoma disseminatum (XD) 146–7, 294–6, 305–6
- skull base lesions 210–11
- smoking as risk factor 8, 194–5, 201, 278

**425**      **Index**

- soft tissue disease, LCH 20, 103, 235
- spinal fluid, familial HLH 328–9
- spine, in LCH 156–7
  - differential diagnosis 157
  - therapy 168
- spleen
  - familial HLH 326
  - LCH 31–2, 115
- stem cell transplantation (SCT)
  - HLH 361–6, 365
    - Epstein–Barr virus-associated 369–70
  - LCH 259–63
- steroid therapy
  - bone disease 165, 236
  - HLH 359, 361, 364, 365
  - lung disease 201–2, 238
  - macrophage-activation syndrome 390–1
  - sinus histiocytosis with massive
    - lymphadenopathy (SHML) 313, 314
  - skin disease 238
- systemic lupus erythematosus 384–5
- systemic-onset juvenile rheumatoid arthritis (SoJRA) 382, 382–4
  
- T cell activation 44–5
- temporal bone, in LCH 157–8
  - differential diagnosis 158
  - therapy 168–9
  
- thalidomide 257–8
- thymus involvement, LCH 33–4, 115
- thyroid involvement, LCH 278
  - histopathology 34
- Toll-like receptors (TLRs) 43–4
- tumours, LCH association 281–2
  
- vertebra plana 98, 156–7, 275
- viral infection
  - role in LCH 76–7, 84
  - see also* Epstein–Barr virus-associated HLH (EBV-HLH)
  
- X-linked lymphoproliferative disease (XLP) 347–8, 356, 357
  - Epstein–Barr virus-triggered
    - hemophagocytosis 347
  - SAP mutations 348
  - SAP role in cytotoxicity 348
- xanthogranuloma (XG)
  - adult 303–4
  - necrobiotic 147
  - see also* juvenile xanthogranuloma (JXG)
- xanthoma disseminatum (XD) 146–7, 294–6, 305–6